Additionally, ipilimumab, an anti-CTLA-4 antibody, is presently being studied as a possible therapeutic option for a range of cancer types, including prostate cancer, non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and other malignancies (87). Here, CTLA4 is linked to non-small cell lung carcinoma.